Navigation Links
Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
Date:1/25/2008

NDC NUMBERS 0641-2440-45, 0641-2440-41, 0641-2450-45 and 0641-2450-41; LOTS: 107054, 117085, 047056, 097081, 107024, 107064, 107066, 107074,

107111

DEERFIELD, Ill., Jan. 25 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation has announced the voluntary recall of nine lots of heparin sodium injection 1000 units/mL 10mL and 30mL multi-dose vials. The company began recalling the lots on January 17, 2008 as a precautionary measure due to an increase in the number of reports of adverse patient reactions that may be associated with the product. Baxter is conducting a thorough investigation of these reports to identify the cause of the increase in allergic-type reactions.

Adverse patient reactions have included: stomach pain or discomfort, nausea, vomiting, diarrhea, decreased or low blood pressure, chest pain, fast heart rate, dizziness, fainting, unresponsiveness, shortness of breath, feeling your heart beat strong or fast, drug ineffectiveness, burning sensation, redness or paleness of skin, abnormal sensation of the skin, mouth or lips, flushing, increased sweating, decreased skin sensitivity, headache, feeling unwell, restlessness, watery eyes, throat swelling, thirst and difficulty opening the mouth. Some of these reactions may be severe or life threatening.

Heparin is a prescription, injectable blood anticoagulant (also called a blood thinner). The 1,000 units/mL multi-dose vials are primarily used for hemodialysis and cardiac invasive procedures. To date, the company has not observed a significant increase in adverse event reports occurring with any other of its heparin presentations.

Customers have been instructed to discontinue use and segregate the recalled product from the rest of their inventory. Customers should then contact Baxter to arrange for return and replacement product. Customers with recalled product purchased indirectly should contact their wholesaler or distributor for re
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Baxter International Fourth Quarter 2007 Financial Results Conference Call
2. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
3. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
4. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
7. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
8. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
9. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
10. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... CA (PRWEB) July 23, 2014 ... cell therapy in the US aimed at improving the ... their newest clinical study for Parkinson’s disease. StemGenex ... of stem cell therapy are paramount when providing care ... clinical study makes stem cell therapy accessible to the ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... , July 23, 2014 regulated information ... research and development pipeline with positive topline results ... brivaracetam . This study was designed to evaluate the ... and 200 mg/day, without titration) compared to placebo, ... with partial-onset seizures, not fully controlled despite treatment ...
(Date:7/23/2014)... VEGAS , July 23, 2014  GrowBLOX Sciences, Inc. ... today that it is filing for two medical marijuana dispensary ... locations are in addition to the Clark County, ... a special use permit, as previously announced.  GrowBLOX ... to be submitting two new applications for dispensaries in the ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... Jan. 29 ChemDiv, Inc., a leading,chemistry-driven ... it has entered into a discovery collaboration ... its expertise in medicinal and synthetic,chemistry, ChemDiv ... antibacterial compounds. Financial terms of the collaboration ...
... (Nasdaq: ALTH ), a biopharmaceutical company focused ... for,the treatment of cancer, today announced that members ... overview at the 2008 Merrill,Lynch Global Pharmaceutical, Biotechnology ... Company,s presentation will take place at 11:00 a.m. ...
... Jan. 29 Edwards Lifesciences,Corporation (NYSE: EW ), ... announced that it has received conditional approval from the ... to the U.S. pivotal,clinical trial of the Edwards SAPIEN ... of the Ascendra transapical,delivery system to the trial, and ...
Cached Biology Technology:ChemDiv and Achaogen Enter Into a Discovery Collaboration 2Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 2Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 3
(Date:7/23/2014)... , , , , , , , , ... , , , , , ... researchers are proposing that changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be ... , , , , , ... , , , , , ...
(Date:7/23/2014)... its grip is affecting more than the color of people,s ... a heat-loving amoeba commonly found in warm freshwater bodies, such ... made warmer than usual this year. , A 9-year-old Kansas ... after swimming in several area lakes. The amoeba enters the ... the brain. Nose plugs can lower the odds of this ...
(Date:7/23/2014)... soil releases about 60 billion tons of carbon into ... that released by burning fossil fuels. This happens through ... carbon is balanced by carbon coming into the soil ... well as by the underground activities of plant roots. ... temperatures increase the rate of soil respiration. As a ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Diseases of another kind 2Climate change and the soil 2
... Wildlife Conservation Society and the State Institute of Animal Health ... of the first health assessments of white-lipped peccaries (medium-sized pig-like ... gauge the impact of Leptospirosis a zoonotic bacteria that ... wildlife and livestock. The studyconducted between 2003 and ...
... HAMILTON, ON (March 23, 2011) - A lot of chatter ... of it happens between our ears. Researchers at McMaster ... and our brain plays an important role in the development ... as well including obesity. "The wave of the future ...
... Researchers at Rice University have created a synthetic ... the body strengthens bones and muscles after repeated workouts. ... professor in mechanical engineering and materials science and of ... carbon nanotube fillers. The team reported its discovery this ...
Cached Biology News:Monitoring peccaries in Brazil benefits wildlife, local communities and food security 2Monitoring peccaries in Brazil benefits wildlife, local communities and food security 3'Knowing it in your gut' is real 2Rice University lab creates self-strengthening nanocomposite 2Rice University lab creates self-strengthening nanocomposite 3
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Self Closing Forceps...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... 1 outflow Single-cell and patch delivery ... solution change Very small dead volume , ... 360, 250 and 100 micron delivery tips ... micromanipulator Available in 4, 8, and 16 ...
Biology Products: